Athenex Inc’s (ATNX) Quiet Period Will Expire on July 24th
Athenex’s (NASDAQ:ATNX) quiet period will expire on Monday, July 24th. Athenex had issued 6,000,000 shares in its initial public offering on June 14th. The total size of the offering was $66,000,000 based on an initial share price of $11.00. During the company’s quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
Separately, Deutsche Bank AG began coverage on Athenex in a research note on Monday, July 10th. They set a “buy” rating and a $20.00 price objective on the stock.
Athenex (NASDAQ:ATNX) opened at 18.82 on Monday. The stock’s market cap is $1.07 billion. The firm’s 50 day moving average price is $14.94 and its 200 day moving average price is $14.94. Athenex has a 12 month low of $11.21 and a 12 month high of $20.79.
In related news, Director Song-Yi Zhang acquired 328,637 shares of the stock in a transaction that occurred on Monday, June 19th. The stock was purchased at an average price of $11.00 per share, with a total value of $3,615,007.00. Following the transaction, the director now owns 4,000 shares of the company’s stock, valued at approximately $44,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Johnson Yiu Nam Lau acquired 25,200 shares of the stock in a transaction that occurred on Monday, June 19th. The shares were bought at an average cost of $11.00 per share, with a total value of $277,200.00. Following the transaction, the chief executive officer now directly owns 2,722,722 shares in the company, valued at approximately $29,949,942. The disclosure for this purchase can be found here.
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.